外科置入微轴左心室辅助装置作为桥接:高容量中心经验
本研究基于单中心临床注册数据,纳入2014年1月至2022年3月接受Impella 5.0或5.5植入的心源性休克患者221例,主要终点为存活至装置移除,结果为70.1%患者存活至Impella移除,Impella 5.5较近期Impella 5.0患者装置更换率更低。
要点
- 221例心源性休克患者中,70.1%(n=155)存活至Impella移除。
- Impella 5.5组装置更换率4.0%(n=3)低于近期Impella 5.0组的13.3%(n=10),P=0.04。
- 中位桥接时长14天(范围0-137天),装置更换、缺血性卒中及同侧上肢缺血分别发生于8.1%、2.7%和1.8%的患者。
核心结论
- Impella 5.0和5.5可为经适当选择的心源性休克患者提供安全有效的临时机械支持。
- 较新的装置代次与前一版本相比,可能具有更低的装置更换需求。
研究设计与样本
- 本研究为高容量中心的机构临床注册研究,纳入2014年1月至2022年3月接受Impella 5.0或5.5植入的所有心源性休克患者。
- 研究队列共221例患者,其中Impella 5.0组146例(66.1%),Impella 5.5组75例(33.9%)。
主要发现
- 主要病因包括非缺血性心肌病(50.7%,n=112)、缺血性心肌病(23.1%,n=51)和急性心肌梗死(26.2%,n=58)。
- 患者按策略前瞻性分类为桥接至移植(47.5%,n=105)、桥接至耐久装置(13.6%,n=30)或桥接至恢复(38.9%,n=86)。
- 患者主要为Interagency Registry for Mechanically Assisted Circulatory Support profile 1或2(95.0%,n=210)。
- 中位桥接时长为14天(范围0-137天)。
- 装置更换、缺血性卒中和同侧上肢缺血分别发生于8.1%(n=18)、2.7%(n=6)和1.8%(n=4)的患者。
临床怎么用
- 原文结论认为Impella 5.0和5.5可为经适当选择的心源性休克患者提供安全有效的临时机械支持。
- 原文结论认为较新的装置代次与前一版本相比,可能具有更低的装置更换需求。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The Impella 5.0 and 5.5 have largely superseded non-ambulatory temporary mechanical support devices; yet, clinical outcomes are predominantly limited to small series: this study presents the experience of a high-volume centre. METHODS: An institutional clinical registry was used to identify all patients with cardiogenic shock who underwent Impella 5.0 or 5.5 implantation from January 2014 to March 2022. The primary outcome was survival to device explantation. RESULTS: The study cohort comprised 221 patients, including 146 (66.1%) Impella 5.0 and 75 (33.9%) Impella 5.5 patients. The primary aetiology was non-ischaemic cardiomyopathy (50.7%, n = 112), ischaemic cardiomyopathy (23.1%, n = 51) and acute myocardial infarction (26.2%, n = 58). Patients were prospectively classified according to strategy as bridge to transplant (47.5%, n = 105), bridge to durable device (13.6%, n = 30) or bridge to recovery (38.9%, n = 86). Patients were predominantly Interagency Registry for Mechanically Assisted Circulatory Support profile 1 or 2 (95.0%, n = 210). The median bridging duration was 14 (range 0-137) days. Device exchange, Ischaemic stroke and ipsilateral arm ischaemia occurred in 8.1% (n = 18), 2.7% (n = 6) and 1.8% (n = 4) of patients, respectively. Compared to the 75 most recent Impella 5.0 patients, Impella 5.5 patients (n = 75) had lower rates of device exchange (4.0%, n = 3 vs 13.3%, n = 10, P = 0.04). Overall, 70.1% (n = 155) of patients survived to Impella explantation. CONCLUSIONS: The Impella 5.0 and 5.5 provide safe and effective temporary mechanical support in appropriately selected patients with cardiogenic shock. The newer device generation may have a lower requirement for device exchange as compared to its predecessor.
引用
- Gill G, Rowe G, Chen Q, et al. Bridging with surgically placed microaxial left ventricular assist devices: a high-volume centre experience. Eur J Cardiothorac Surg. 2023. PMID: 36975609. doi:10.1093/ejcts/ezad116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。